Ryvu Therapeutics SA operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Ryvu Therapeutics SA with three other
miscellaneous service companies in Europe:
sales of 18.19 million Euro [US$20.08 million]
of which 98%
(20.09 million Euro [US$22.17 million]
Puretech Health Plc
based in the United Kingdom
(£15.59 million [US$20.04 million]
of which 89%
During the year ended December of 2018, sales at
Ryvu Therapeutics SA were 77.21 million Polish New Zlotys (US$19.93 million).
increase of 14.3%
versus 2017, when the company's sales were 67.54 million Polish New Zlotys.
This was the fifth consecutive year of sales increases at Ryvu Therapeutics SA
(and since 2013, sales have increased a total of 491%).
Sales of Services saw an increase
that was more than double the company's growth rate: sales were up
33.6% in 2018, from
44.21 million Polish New Zlotys to 59.08 million Polish New Zlotys.
Ryvu Therapeutics SA also saw significant increases in sales in
Bioinformatic (up 24.3% to 8.56 million Polish New Zlotys)
Not all segments of Ryvu Therapeutics SA experienced an increase in sales in 2018:
sales of Innovative fell 73.5% to 9.74 million Polish New Zlotys.